Valneva SE (VALN) confirmed the previously announced timelines of its clinical trials and regulatory submissions for inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company continues to expect potential regulatory approvals in the first quarter of 2022. Also, Valneva expects to report topline data for the elderly trial in the coming weeks.

Create Account

Dark

chart

exchange

Check out our Level2View

Valneva SE (VALN) confirmed the previously announced timelines of its clinical trials and regulatory submissions for inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company continues to expect potential regulatory approvals in the first quarter of 2022. Also, Valneva expects to report topline data for the elderly trial in the coming weeks.

RTTNews | Jan 6, 2022 01:18AM EST

01:18 Thursday, January 6, 2022 (RTTNews.com) - Valneva SE (VALN) confirmed the previously announced timelines of its clinical trials and regulatory submissions for inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company continues to expect potential regulatory approvals in the first quarter of 2022. Also, Valneva expects to report topline data for the elderly trial in the coming weeks.

Valneva said it is preparing to launch a dedicated heterologous booster trial, which will evaluate a VLA2001 booster shot provided at least six months after primary vaccination with licensed COVID-19 vaccines or following natural COVID-19 infection.

Read the original article on RTTNews ( https://www.rttnews.com/3253062/valneva-continues-to-expect-potential-regulatory-approvals-for-covid-19-vaccine-candidate-in-q1.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved